Nous utilisons des cookies
En cliquant sur « Accepter », vous acceptez que des cookies soient stockés sur votre appareil afin d'améliorer la navigation sur le site, d'analyser l'utilisation du site et de nous aider dans nos efforts de marketing. Consultez nos mentions légales pour plus d'informations.
Actualités & Perspectives

EFPIA, An Urgent Call to Action


🚀 Revitalizing Europe's Life Sciences Sector: An Urgent Call to Action 🌍

At this pivotal moment of political change in Europe, EFPIA - European Federation of Pharmaceutical Industries and Associations is urging EU leaders to collaborate with the industry to reclaim our region's status as a global leader in life sciences. The proposal? A robust Competitiveness Strategy and the establishment of a dedicated Office for European Life Sciences within the European Commission.

The aim is clear: align with the ambitions of European Heads of State and Government, restore Europe's competitive edge, and boost EU health resilience and strategic autonomy. 📈

Key Insights from EFPIA’s latest report: Global Competition: In 2023, China surpassed Europe in launching new active substances, highlighting the urgent need for action.R&D Investment Decline: Europe has lost 25% of its global R&D investment over the past 20 years.Clinical Trials: Europe's share of clinical trials has fallen by a quarter in the last decade.

EFPIA's Five Strategic Recommendations:

1️- EU Office for Life Sciences: Centralized leadership and policy coherence.

2️- Innovation Ecosystem: Foster biotech and pharma clusters, support start-ups, and strengthen venture capital.

3️- Competitive Manufacturing Hub: Enhance STEM education, develop agile clinical trials, and attract modern manufacturing investments.

4- Health Investment: Recognize health expenditure as future investment and support healthcare system enhancements.

5️- Resilient Biopharma Leadership: Secure robust funding for the EMA and align regulatory frameworks globally.

Let's unite for a competitive, healthier, and stronger Europe! 🌟